Epigral (EPIGRAL) Aktienübersicht
Epigral Limited produziert und vertreibt Chloralkali und verwandte Derivate in Indien und international. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 3/6 |
| Künftiges Wachstum | 3/6 |
| Vergangene Leistung | 2/6 |
| Finanzielle Gesundheit | 6/6 |
| Dividenden | 3/6 |
EPIGRAL Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Epigral Limited Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | ₹1,127.60 |
| 52-Wochen-Hoch | ₹2,114.00 |
| 52-Wochen-Tief | ₹807.00 |
| Beta | 0.18 |
| 1 Monat Veränderung | -11.22% |
| 3 Monate Veränderung | 33.33% |
| 1 Jahr Veränderung | -34.87% |
| 3 Jahre Veränderung | -0.78% |
| 5 Jahre Veränderung | n/a |
| Veränderung seit IPO | 177.43% |
Aktuelle Nachrichten und Updates
Narrativ-Update • Jun 07
EPIGRAL: Steady ₹2,000 View Will Reflect 2026 Board Meeting Outcomes
Analysts have kept Epigral's fair value estimate steady at ₹2,000. They point to broadly unchanged assumptions on discount rate, revenue growth, profit margin and future P/E as the basis for maintaining their price target view.Narrativ-Update • May 24
EPIGRAL: Steady ₹2,000 View Will Reflect 2026 Board Meeting Outcomes
Analysts are keeping the fair value estimate for Epigral steady at ₹2,000, citing slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E as the key drivers behind the updated price target framework. What's in the News Board meeting scheduled for May 2, 2026, to review audited standalone and consolidated financial results for the fourth quarter and full year ended March 31, 2026, and to consider the statutory auditors' report (company filing).Recent updates
Narrativ-Update • Jun 07
EPIGRAL: Steady ₹2,000 View Will Reflect 2026 Board Meeting Outcomes
Analysts have kept Epigral's fair value estimate steady at ₹2,000. They point to broadly unchanged assumptions on discount rate, revenue growth, profit margin and future P/E as the basis for maintaining their price target view.Narrativ-Update • May 24
EPIGRAL: Steady ₹2,000 View Will Reflect 2026 Board Meeting Outcomes
Analysts are keeping the fair value estimate for Epigral steady at ₹2,000, citing slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E as the key drivers behind the updated price target framework. What's in the News Board meeting scheduled for May 2, 2026, to review audited standalone and consolidated financial results for the fourth quarter and full year ended March 31, 2026, and to consider the statutory auditors' report (company filing).Analyseartikel • May 08
Epigral Limited's (NSE:EPIGRAL) Sole Analyst Just Made A Substantial Upgrade To Their Forecasts
Celebrations may be in order for Epigral Limited ( NSE:EPIGRAL ) shareholders, with the covering analyst delivering a...Narrativ-Update • Apr 21
EPIGRAL: Steady ₹2,000 View Ahead Of 2026 Postal Ballot Outcome
Epigral's analyst fair value estimate is maintained at ₹2,000, with only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, as analysts fine tune their model inputs rather than changing their core view on the stock. What's in the News Epigral has scheduled a Special or Extraordinary Shareholders Meeting on May 19, 2026, to be conducted via postal ballot in India (Key Developments).Narrativ-Update • Apr 06
EPIGRAL: Steady ₹2,000 View Will Await Q3 Board Outcome
Analysts now keep Epigral's fair value estimate broadly unchanged at about ₹2,000 per share, with only minor tweaks to discount rate, revenue growth, profit margin and future P/E assumptions. This signals a largely steady view on the stock's valuation drivers.Narrativ-Update • Mar 23
EPIGRAL: Steady ₹2,000 Outlook Will Anticipate Q3 Board Meeting Outcome
Analysts have kept Epigral's fair value estimate steady at ₹2,000, with only minor tweaks to the discount rate, revenue growth, profit margin assumptions and future P/E supporting an unchanged price target. What's in the News A board meeting is scheduled on January 30, 2026 to consider the unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025, along with the limited review report.Narrativ-Update • Mar 08
EPIGRAL: Steady ₹2,000 Fair Value Will Anticipate Q3 Board Review Outcome
Analysts have kept Epigral’s fair value estimate steady at ₹2,000, with only small tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E. This reflects fine tuning of their models rather than a material change in conviction.Narrativ-Update • Feb 21
EPIGRAL: Reaffirmed ₹2,000 Fair Value Will Support Future Repricing
Analysts have maintained Epigral's fair value estimate at ₹2,000. A slightly lower assumed future P/E and a marginally higher discount rate together support this unchanged price target.Narrativ-Update • Feb 07
EPIGRAL: New CFO And Reaffirmed Fair Value Will Support Future Repricing
Analysts now see fair value for Epigral at ₹2,000.00 per share, with the unchanged target based on updated assumptions on discount rate, revenue growth, profit margin and future P/E that together reflect a recalibration of their long term earnings and valuation framework. What's in the News A board meeting is scheduled on January 30, 2026 to consider unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025, along with the limited review report from statutory auditors (company filing).Narrativ-Update • Jan 24
EPIGRAL: New CFO And Reaffirmed Fair Value Will Support Future Repricing
Analysts have maintained Epigral's fair value estimate at ₹2,000 after updating their assumptions for discount rate, revenue growth, profit margin and future P/E. These revisions support a recalibrated price target narrative rather than a change in the overall valuation direction.Narrativ-Update • Jan 09
EPIGRAL: New CFO Appointment Is Expected To Strengthen Future Financial Governance
Analysts have cut their price target on Epigral from ₹2,600 to ₹2,000, citing updated assumptions that combine slightly higher revenue growth and profit margins with a lower future P/E multiple. What's in the News Epigral appointed Mr. Rakesh Agrawal as Chief Financial Officer and Key Managerial Personnel, effective 10 November 2025, following a board decision based on the Nomination and Remuneration Committee's recommendation (Key Developments).Analyseartikel • Dec 26
Returns On Capital At Epigral (NSE:EPIGRAL) Have Hit The Brakes
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...Analyseartikel • Nov 16
Downgrade: What You Need To Know About The Latest Epigral Limited (NSE:EPIGRAL) Forecasts
Market forces rained on the parade of Epigral Limited ( NSE:EPIGRAL ) shareholders today, when the covering analyst...Analyseartikel • Nov 13
Epigral Limited Just Missed Earnings - But Analysts Have Updated Their Models
Epigral Limited ( NSE:EPIGRAL ) shareholders are probably feeling a little disappointed, since its shares fell 9.0% to...Analyseartikel • Nov 11
If EPS Growth Is Important To You, Epigral (NSE:EPIGRAL) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analyseartikel • Sep 28
Epigral (NSE:EPIGRAL) Has A Pretty Healthy Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Narrativ-Update • Aug 06
Capacity Expansion And Green Energy Will Unlock Global Opportunities
The increase in Epigral’s consensus analyst price target to ₹2600 primarily reflects higher anticipated future earnings multiples, as indicated by the rise in future P/E, while the discount rate remains stable. What's in the News Upcoming board meeting to consider un-audited Q1 FY26 results and review fund-raising proposals via debt instruments.Analyseartikel • Aug 06
Epigral Limited Just Recorded A 98% EPS Beat: Here's What Analysts Are Forecasting Next
NSEI:EPIGRAL 1 Year Share Price vs Fair Value Explore Epigral's Fair Values from the Community and select yours As you...Analyseartikel • Jul 30
Epigral Limited (NSE:EPIGRAL) Might Not Be As Mispriced As It Looks
With a price-to-earnings (or "P/E") ratio of 23.6x Epigral Limited ( NSE:EPIGRAL ) may be sending bullish signals at...Analyseartikel • Jun 02
Investors Should Be Encouraged By Epigral's (NSE:EPIGRAL) Returns On Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...Analyseartikel • Apr 03
Subdued Growth No Barrier To Epigral Limited (NSE:EPIGRAL) With Shares Advancing 25%
Epigral Limited ( NSE:EPIGRAL ) shareholders would be excited to see that the share price has had a great month...Analyseartikel • Feb 28
Calculating The Fair Value Of Epigral Limited (NSE:EPIGRAL)
Key Insights Epigral's estimated fair value is ₹1,644 based on 2 Stage Free Cash Flow to Equity With ₹1,630 share...
Neues Narrativ • Jan 16
Doubling CPVC And ECH Production Will Strengthen Future Prospects
Epigral is expanding production capacity and focusing on high-margin value-added products to enhance earnings and future growth.Analyseartikel • Dec 18
Here's Why Epigral (NSE:EPIGRAL) Has Caught The Eye Of Investors
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analyseartikel • Jul 04
Epigral Limited's (NSE:EPIGRAL) Shares Leap 29% Yet They're Still Not Telling The Full Story
Epigral Limited ( NSE:EPIGRAL ) shareholders would be excited to see that the share price has had a great month...Analyseartikel • Apr 19
Epigral Limited (NSE:EPIGRAL) Looks Just Right With A 27% Price Jump
The Epigral Limited ( NSE:EPIGRAL ) share price has done very well over the last month, posting an excellent gain of...Analyseartikel • Feb 23
Epigral Limited (NSE:EPIGRAL) Soars 28% But It's A Story Of Risk Vs Reward
Despite an already strong run, Epigral Limited ( NSE:EPIGRAL ) shares have been powering on, with a gain of 28% in the...Analyseartikel • Feb 21
Epigral (NSE:EPIGRAL) Might Be Having Difficulty Using Its Capital Effectively
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...Analyseartikel • Apr 05
Capital Investment Trends At Meghmani Finechem (NSE:MFL) Look Strong
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...Analyseartikel • Sep 28
With EPS Growth And More, Meghmani Finechem (NSE:MFL) Makes An Interesting Case
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Aktionärsrenditen
| EPIGRAL | IN Chemicals | IN Markt | |
|---|---|---|---|
| 7D | 1.1% | 2.6% | 2.8% |
| 1Y | -34.9% | -0.4% | 0.9% |
Rendite im Vergleich zur Industrie: EPIGRAL unter dem Niveau der Branche Indian Chemicals , die im vergangenen Jahr eine Rendite von -0.4% erzielte.
Rendite vs. Markt: EPIGRAL hinter dem Markt Indian zurück, der im vergangenen Jahr eine Rendite von 0.9 erzielte.
Preisvolatilität
| EPIGRAL volatility | |
|---|---|
| EPIGRAL Average Weekly Movement | 7.3% |
| Chemicals Industry Average Movement | 7.2% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in IN Market | 10.2% |
| 10% least volatile stocks in IN Market | 4.6% |
Stabiler Aktienkurs: EPIGRAL hatte in den letzten 3 Monaten im Vergleich zum Indian -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: EPIGRALDie wöchentliche Volatilität (7%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2007 | 1,135 | Kaushal Soparkar | www.epigral.com |
Epigral Limited produziert und vertreibt Chloralkali und verwandte Derivate in Indien und international. Das Unternehmen bietet Harze aus chloriertem Polyvinylchlorid (CPVC), Epichlorhydrin, die Wertschöpfungskette von Chlormethanen, Wasserstoffperoxid, Natronlauge, Chlor, Wasserstoff und Kalilauge an. Das Unternehmen ist auch im Handel mit agrochemischen Produkten tätig.
Epigral Limited's Grundlagenzusammenfassung
| EPIGRAL grundlegende Statistiken | |
|---|---|
| Marktanteil | ₹48.65b |
| Gewinn(TTM) | ₹3.32b |
| Umsatz(TTM) | ₹25.27b |
14.7x
Kurs-Gewinn-Verhältnis 1.9x
Kurs-Umsatz-VerhältnisIst EPIGRAL zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| EPIGRAL Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | ₹25.27b |
| Kosten der Einnahmen | ₹15.75b |
| Bruttogewinn | ₹9.52b |
| Sonstige Ausgaben | ₹6.20b |
| Gewinn | ₹3.32b |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 76.95 |
| Bruttomarge | 37.69% |
| Nettogewinnspanne | 13.14% |
| Schulden/Eigenkapital-Verhältnis | 25.3% |
Wie hat sich EPIGRAL auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
0.4%
Aktuelle Dividendenrendite6%
AusschüttungsquoteZahlt EPIGRAL eine zuverlässige Dividende?
Siehe EPIGRAL Dividendenhistorie und Benchmarks| Epigral Dividendentermine | |
|---|---|
| Ex-Dividenden Datum | Jun 01 2026 |
| Datum der Dividendenzahlung | Jul 08 2026 |
| Tage bis Ex-Dividende | 21 days |
| Tage bis zum Datum der Dividendenzahlung | 16 days |
Zahlt EPIGRAL eine zuverlässige Dividende?
Siehe EPIGRAL Dividendenhistorie und BenchmarksUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/20 18:39 |
| Aktienkurs zum Tagesende | 2026/06/19 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2026/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Epigral Limited wird von 3 Analysten beobachtet. 1 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| null null | BP Wealth Management Private Limited |
| null null | Emkay Global Financial Services Ltd. |
| Meet Vora | Emkay Global Financial Services Ltd. |